Bevacizumab biosimilar (TOT Biopharm)

贝伐珠单抗生物类似药（东曜药业）

Report date: 2025/11/18 14:57:35

Base Information

Drug NameBevacizumab biosimilar (TOT Biopharm)
Drug Alias Namebevacizumab biosimilar（TOT Biopharm）贝伐珠单抗生物仿制药（东曜药业）TAB008单抗贝伐单抗生物仿制药（东曜药业）贝伐单抗生物类似药（东曜药业） +[14] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Biosimilar
Mechanisms of ActionVascular endothelial growth factor A inhibitors
TargetsVascular endothelial growth factor A
Therapy Area/IndicationsUterine Cervical NeoplasmsFallopian Tube NeoplasmsCarcinoma, Non-Small-Cell Lung +[7] 
Global Approved IndicationsCarcinoma, Non-Small-Cell LungColorectal Neoplasms
Approved Indications in ChinaCarcinoma, Non-Small-Cell LungColorectal Neoplasms
Original Approved Country/TerritoryMainland China
Original Approved Date2021/12/01
Country/TerritoryNigeriaBoliviaMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesTot Biopharm Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesShenzhen Keyi Pharmaceutical Holdings Co LtdJiangxi Jemincare Group Co LtdShandong Kexing Bio-Products Co Ltd +[4] 
Inactive CompaniesN/A
Active IndicationsUterine Cervical NeoplasmsFallopian Tube NeoplasmsCarcinoma, Non-Small-Cell Lung +[7] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A